Samarth Kumar

Samarth Kumar

Auto-generated profile, based on publicly available information

Samarth Kumar


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
SSSachin N. Sanap
Sachin N. Sanap
MVMilan Vasoya
Milan Vasoya
MHMayank Handa
Mayank Handa
PPPrachi Pandey
Prachi Pandey
KSKrutika Sawant
Krutika Sawant

15 March 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
SSSachin N. Sanap
Sachin N. Sanap
MVMilan Vasoya
Milan Vasoya
MHMayank Handa
Mayank Handa
PPPrachi Pandey
Prachi Pandey
KSKrutika K. Sawant
Krutika K. Sawant

18 September 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
NGNeeraj Kumar Garg
Neeraj Kumar Garg
AJAshay Jain
Ashay Jain
AKAjay Khopade
Ajay Khopade
PPPrachi Pandey
Prachi Pandey
KSKrutika Sawant
Krutika Sawant

13 January 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
SSSachin N. Sanap
Sachin N. Sanap
PPPrachi Pandey
Prachi Pandey
AKAjay Khopade
Ajay Khopade
KSKrutika Sawant
Krutika Sawant

12 January 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
NGNeeraj Kumar Garg
Neeraj Kumar Garg
AJAshay Jain
Ashay Jain
PPPrachi Pandey
Prachi Pandey
AKAjay Khopade
Ajay Khopade
KSKrutika Sawant
Krutika Sawant

29 July 2024 in Therapeutic Delivery
Verified
Journal Article
Closed access
SKSamarth Kumar
Samarth Kumar
ASAjit Singh
Ajit Singh
PPPrachi Pandey
Prachi Pandey
AKAjay Khopade
Ajay Khopade
KSKrutika Sawant
Krutika Sawant
Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer's disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.